Skip to content
Bored Studies
RecruitingPhase 1

A Study of CDX-622 in Participants With Mild to Moderate Asthma

Celldex Therapeutics · NCT07330778

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 1
Target enrollment
12
US sites recruiting
4
Study start
June 1, 2026
Record last updated
July 2, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This is a study to determine the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of CDX-622 in adults with mild to moderate asthma.

Being studied: CDX-622

Conditions: Mild to Moderate Asthma

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Key Inclusion Criteria

  • Males and females, ≥ 18 years of age
  • Diagnosis of mild to moderate asthma for at least 12 months
  • Pre-bronchodilator forced expiratory volume in 1 second (FEV1) ≥ 70% of predicted normal
  • Airway reversibility ≥ 12% and 200 mL improvement in FEV1
  • Both males and females of child-bearing potential must agree to use contraception during the study and for 150 days after treatment
  • Willing and able to comply with all study requirements and procedures

Key Exclusion Criteria

  • Females who are pregnant or nursing
  • Pulmonary disease other than asthma
  • Systemic diseases with elevated eosinophils other than asthma
  • Hospitalization for treatment of asthma in the past 12 months or required oral corticosteroids due to asthma within the past 6 months
  • History of needing ventilator support due to asthma
  • Current nasal polyps
  • Severe or uncontrolled asthma
  • History of smoking or vaping within the past 6 months
  • Tuberculosis, hepatitis B or C virus, or HIV
  • Immunomodulating biologic therapies within the past 3 months for non-extended half-life biologics.
  • Prior receipt of TSLP or KIT inhibitors such as tezepelumab or briquilimab

Additional protocol defined inclusion and exclusion criteria could apply.

Recruiting US locations

  • University of California, San Francisco

    San Francisco, CA 94143

    Site contact: Mariana Mosqueda · Mariana.Mosqueda@ucsf.edu

  • The University of Kansas Medical Center

    Kansas City, KS 66160

    Site contact: Jamie Quigley, RRT, RPFT, AE-C, CCRC · 913-574-3036 · jtroxel@kumc.edu

  • Brigham and Women's Hospital

    Boston, MA 02115

    Site contact: Maria Angeles Cinelli · arc@bwh.harvard.edu

  • University of Pittsburgh Asthma and Environmental Lung Health Institute at UPMC

    Pittsburgh, PA 15213

    Site contact: Logan Sullivan · 412-639-0585 · sullivanlt@upmc.edu

Study contacts (from the official record)

  • Celldex Therapeutics · 844-723-9363 · clinicaltrials@celldex.com
All phase 1 studies in California →
A Study of CDX-622 in Participants With Mild to Moderate Asthma (NCT07330778) | Bored Studies